One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Amryt Pharma plc logo
Amryt Pharma plc AMYT
report update icon

Quarterly report 2021-Q4
added 05-23-2026

Amryt Pharma plc Income Statement 2021-2011 | AMYT

Brief overview of financial performance at Amryt Pharma plc

The overview follows changes across a five-year period. Revenue at Amryt Pharma plc moved from $1.4 million in 2016 to $223 million in 2021. Overall revenue changed by +15562.7%, equal to an annualized rate of about 174.8%. The company expanded its revenue base at a high speed.

At the gross-profit level, the result moved from 805 thousand dollars to 116 million dollars, a change of +14370.7%. Gross margin moved from 56.6% to 52.3%. A lower margin indicates deterioration in the economics of the core business.

The five-year EBITDA result moved by −548.2%: from −$6 million to −$38.6 million. Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −419% and −17.3%. The business generated more EBITDA from each unit of revenue.

The net financial result changed from −$8.2 million to $1 million. The trajectory reversed from a loss to positive earnings.

What the figures show

The figures do not all move in the same direction. The positive side is supported by improving net profitability, sales growth and an improving EBITDA margin. Caution is warranted because of a low EBITDA margin and a lower gross margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.55 B 2.25 B - - - - - - - - -

Shares

236 M 159 M 75.9 M 45.8 M - - - - - - -

Historical Prices

10.8 14.2 - - - - - - - - -

Net Income

1 M -105 M -63 M -30.5 M -31.4 M -8.21 M -39.7 M -2.56 M -2.12 M -826 K -3.06 M

Revenue

223 M 183 M 58.1 M 17.1 M 15.3 M 1.42 M - - - - -

Cost of Revenue

106 M 119 M 38.7 M 6.27 M - - - - - - -

Gross Profit

116 M 63.6 M 19.4 M 10.8 M 8.88 M 805 K - - - - -

Operating Income

-38.6 M -46.5 M -50.5 M -18 M - - - - - - -

EBITDA

-38.6 M -46.5 M -50.5 M -18 M -16.7 M -5.95 M 33.3 M -2.93 M -202 K -275 K -281 K

Operating Expenses

- 109 M 52.2 M 27.9 M 25.9 M 6.95 M - - - - -

General and Administrative Expenses

92 M 76.7 M 35.5 M 17.3 M 13.3 M 4.49 M 3.2 M 2.47 M 1.47 M 275 K 281 K

All numbers in USD currency

Quarterly Income Statement Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 236 M - - - 159 M - - - 75.9 M - - - 45.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - 1 M - - - -105 M - - - -63 M - - - -30.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - 223 M - - - 183 M - - - 58.1 M - - - 17.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - 106 M - - - 119 M - - - 38.7 M - - - 6.27 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - 116 M - - - 63.6 M - - - 19.4 M - - - 10.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - -38.6 M - - - -46.5 M - - - -50.5 M - - - -18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - -38.6 M - - - -46.5 M - - - -50.5 M - - - -18 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - 92 M - - - 76.7 M - - - 35.5 M - - - 17.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Amryt Pharma plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
- - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
- - $ 127 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA